RGX-111

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameRGX-111
Drug Alias NamerAAV9.CB7 .hIDUAAAV9.CB7.hIDUARGX-111
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGene transferenceAlpha-L-iduronidase stimulants
TargetsAlpha-L-iduronidase
Therapy Area/IndicationsMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesBrazil
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegenxbio IncUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegenxbio IncNippon Shinyaku Co Ltd
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis I

Other Information

ATC CodeN/A
Related LinksN/A